Scientific exchange · Dr. Valentina Nakamura

24 Mar 2026 · Virtual · Dr. Valentina Nakamura, MD Anderson Cancer Center · MSL Dr. Anna Becker · Nephrada

ReviewedVeeva CRMENG-0122—

Capture insight from this engagement

Location: MD Anderson Cancer Center
Therapeutic area: Nephrology
Country: United States
Stakeholder tier: Tier 1
Strategic objective: Not linked
Initiative: Not linked
MSL: ABDr. Anna BeckerMSL, Nephrology (DACH)
Product: Nephrada (nephradin)

Topics discussed

Steroid-sparing strategies
APRIL pathway mechanism
Treatment burden and fatigue

Scientific content used

APRIL-IgAN Phase III topline
Surrogate-endpoint evidence review

Questions raised

What is the immunoglobulin monitoring recommendation?
How does proteinuria reduction at 9 months translate to eGFR benefit?

Notes

Scientific exchange with community nephrologist at MD Anderson Cancer Center. Discussed steroid-sparing strategies, april pathway mechanism, treatment burden and fatigue.

Insights captured (0)

Capture insight

No insights captured from this engagement.

Review workflow

Draft
Submitted
3Reviewed

Review complete. Quality ratings and insights can now be used in aggregates.

Follow-ups

No follow-ups recorded.

Quality ratings

1–5, rated at review

Scientific relevance: 2
Strategic relevance: 3
Depth of exchange: 5
Actionability: 2

Data lineage

Source system: Veeva CRM
Sync: Veeva CRM · synced 2026-09-15 08:00 UTC
System of record: Veeva CRM
Record id: ENG-0122

Audit history (0)

All create, update and approval events for this record

No audit events in sample data